Latest research on Desvenlafaxine

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Desvenlafaxine dosage

Dose of Desvenlafaxine in the first 3 weeks was 50 mg/day and 100 mg/day for the next 3 weeks. [source, 2016]
Citalopram,[19] Duloxetine,[23] and esCitalopram,[19] carry a moderate risk while most of the selective serotonin reuptake inhibitors and serotonin Norepinephrine reuptake inhibitors such as - Bupropion,[19] Desvenlafaxine, Levomilnacipran, mianserin, Sertraline, vilazodone[24] and reboxetine[25] are reported to be safe with a low risk of QTc prolongation at therapeutic doses. [source, 2015]
Baseline daily SSRI/SNRI doses were as follows: Sertraline (n = 7) = 86 ± 24 mg; Citalopram (n = 7) = 34 ± 10 mg; esCitalopram (n = 4) = 10 ± 0 mg; fluoxetine (n = 2) = 30 ± 0 mg; Venlafaxine XR (n = 1) = 150 mg; DesVenlafaxine (n = 1) = 100 mg; Fluvoxamine (n = 1) = 50 mg; Paroxetine (n = 2) = 25 ± 0 mg; and Duloxetine (n = 1) = 120 mg. [source, 2015]
One may expect less inter-individual dose variance for Desvenlafaxine given this, but the dose range in clinical settings is large. [source, 2015]
Desvenlafaxine was held at a constant dosage 8 weeks prior to treatment and throughout the course of rTMS. [source, 2015]
There were four other participants who stopped their previous antidepressant treatment between 2 and 4 weeks prior to the baseline [11C]harmine PET scan, and received the following treatments as total daily doses (n = 1 each): Cymbalta (120mg), Desvenlafaxine (50mg), Zoloft (50mg), and Effexor (37.5mg). [source, 2015]
However, the meta-analyses were performed with only Desvenlafaxine doses of 100mg and 150mg. [source, 2014]
Subgroup analysis based on doses of Desvenlafaxine and linear meta-regression analysis for several covariates or moderators (women's age, baseline BMI, baseline severity of hot flashes, duration from menopause and the proportion of women with natural menopause) were conducted to examine the sources of heterogeneity. [source, 2014]
Four of the studies (27, 28, 32, 38) compared the effectiveness and safety of 100mg/day of Desvenlafaxine against placebo; three of the studies (30, 31, 38) tested two doses of Desvenlafaxine (100 mg /day and 150 mg/day) against placebo; and two studies (29, 38) tested four doses of Desvenlafaxine (50 mg/day, 100 mg/day, 150 mg/day and 200 mg/day) against placebo. [source, 2014]
In other two studies (29, 38), although the actual value of the SMD inclines to the left, neither too low (50 mg) nor too high (200 mg) dose of Desvenlafaxine showed statistically significant reduction in the number of daily moderate to severe hot flashes. [source, 2014]